PROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA HANOVER, MD, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...